In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Pressures On US Generics Industry Go Beyond Current Price Squeeze

Executive Summary

Generics firms in the US must fight back against brand industry attempts to thwart competition as well as regulatory obstacles looming on the horizon, while continuing to grapple with ongoing price erosion, says AAM president and CEO Chip Davis.

You may also be interested in...



Viatris And Biocon Line Up EU Bevacizumab

Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.

CMA Sees Fine Over Nortriptyline Upheld In UK

The UK’s Competition and Markets Authority has welcomed a ruling upholding its finding that Lexon broke competition law in relation to nortriptyline, along with a connected £1.2m fine.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.

Topics

Related Companies

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel